Effect of homeopathic medicines for the treatment of Smoking

Effect of Hetero-isotherapics for the treatment of Smoking

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

REBEC

Registry ID

RBR-85tmk64

Enrollment

Unknown

Registered

2025-12-01

Start date

2017-07-26

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tobacco Use Disorder

Interventions

Double-blind, randomized, controlled clinical trial with 84 participants. The Nux vomica control group included 42 smokers and the Heteroisoterapico test group included 42 smokers. The drugs Nux vomi

Eligibility

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Smoking participants; at least 18 years old; both sexes; who wish to give up the habit of smoking; participant must be a current smoker, which is someone who smokes daily or occasionally

Exclusion criteria

Exclusion criteria: Not be a smoker. Just be a passive smoker. Be an ex-smoker. Be under 18 years old. Participants who are included in the research, but refuse to adequately respond to the Follow-up questionnaire or do not attend monthly evaluation meetings with the team. People who have not smoked for at least 1 month (ex-smokers) or who do not smoke or who are passive smokers

Design outcomes

Primary

Measure	Time frame
Expected outcome 1: Tobacco cessation is expected to be measured by the Fagerstrom Test for Cigarette Dependence taken three months after the intervention. ;Expected found 1: There was a between-group difference in tobacco cessation, which was increased (p<0.05) in the hetero-isotherapeutic group (40.0%) compared with the Nux vomica group (21.4%). Thus, the superior efficacy of the individualized hetero-isotherapeutic preparation is demonstrated over the standardized Nux vomica.	—

Measure

Time frame

Expected outcome 1: Tobacco cessation is expected to be measured by the Fagerstrom Test for Cigarette Dependence taken three months after the intervention. ;Expected found 1: There was a between-group difference in tobacco cessation, which was increased (p<0.05) in the hetero-isotherapeutic group (40.0%) compared with the Nux vomica group (21.4%). Thus, the superior efficacy of the individualized hetero-isotherapeutic preparation is demonstrated over the standardized Nux vomica.

—

Secondary

Measure	Time frame
Expected outcome 2: We expect to see a reduction in tobacco dependence as measured by the Fagerstrom Test for Cigarette Dependence taken three months after the intervention. ;Outcome found 2: Both treatments decrease the number of cigarettes smoked per day, with a 60.0% reduction in the hetero-isotherapeutic group and 78.6% in the Nux vomica group (p>0.05). In addition, the data showed the absence of adverse events in both groups.	—

Measure

Time frame

Expected outcome 2: We expect to see a reduction in tobacco dependence as measured by the Fagerstrom Test for Cigarette Dependence taken three months after the intervention. ;Outcome found 2: Both treatments decrease the number of cigarettes smoked per day, with a 60.0% reduction in the hetero-isotherapeutic group and 78.6% in the Nux vomica group (p>0.05). In addition, the data showed the absence of adverse events in both groups.

—

Countries

Brazil

Contacts

Public ContactAdriana Oliveira

Faculdade de Farmácia da Universidade Federal do Rio de Janeiro

adrianapassos@pharma.ufrj.br+55-021-39386621

Outcome results

None listed

Source: REBEC (via WHO ICTRP)